« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Prospective comparison of PSA kinetics following two different prostate cancer brachytherapy planning methods: Preoperative and real-time intraoperative dosimetry planning

  • Haim Matzkin, M.D.

      Affiliations

    • Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Juza Chen, M.D.

      Affiliations

    • Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Amira Stenger, R.N., M.A.

      Affiliations

    • Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Rubi Agai, B.Sc.

      Affiliations

    • Department of Oncology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Nicola J. Mabjeesh, M.D., Ph.D.

      Affiliations

    • Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-3-697-4544; fax: +972-3-697-3183

Received 21 September 2009 ,Revised 30 November 2009 ,Accepted 1 December 2009. Published online 02 March 2010 Corrected Proof

References 

  1. Guedea F, Aguilo F, Polo A, et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1,050 patients with clinical T1–T2 prostate cancer. Radiother Oncol. 2006;80:57–61
  2. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333
  3. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical Stage T1–T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57–64
  4. Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl. 1991;137:113–118
  5. Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 1997;80:442–453
  6. Stock RG, Stone NN, Wesson MF, et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 1995;32:219–225
  7. Stock RG, Stone NN, Lo YC. Intraoperative dosimetric representation of the real-time ultrasound-guided prostate implant. Tech Urol. 2000;6:95–98
  8. Beyer DC, Shapiro RH, Puente F. Real-time optimized intraoperative dosimetry for prostate brachytherapy: A pilot study. Int J Radiat Oncol Biol Phys. 2000;48:1583–1589
  9. Woolsey J, Bissonette E, Schneider BF, et al. Prospective outcomes associated with migration from preoperative to intraoperative planned brachytherapy: A single center report. J Urol. 2004;172:2528–2531
  10. Shanahan TG, Nanavati PJ, Mueller PW, et al. A comparison of permanent prostate brachytherapy techniques: Preplan vs. hybrid interactive planning with postimplant analysis. Int J Radiat Oncol Biol Phys. 2002;53:490–496
  11. Matzkin H, Kaver I, Bramante-Schreiber L, et al. Comparison between two iodine-125 brachytherapy implant techniques: Preplanning and intra-operative by various dosimetry quality indicators. Radiother Oncol. 2003;68:289–294
  12. Zelefsky MJ, Yamada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956–963
  13. Grimm PD, Blasko JC, Ragde H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer. Atlas Urol Clin of North Am. 1994;2:113–125
  14. Stock RG, Stone NN, Tabert A, et al. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  15. Zelefsky MJ, Leibel SA, Wallner KE, et al. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol. 1995;13:459–463
  16. Critz FA, Levinson AK, Williams WH, et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 1997;49:322–326
  17. Wallner K, Merrick G, True L, et al. 125I vs. 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297–1303
  18. Ciezki JP, Reddy CA, Garcia J, et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys. 2006;64:512–517
  19. Crook J, Gillan C, Yeung I, et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007;69:426–433
  20. Prete JJ, Prestidge BR, Bice WS, et al. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys. 1998;40:1001;–5.
  21. Cormack RA, Kooy H, Tempany CM, et al. A clinical method for real-time dosimetric guidance of transperineal 1,25I prostate implants using interventional magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2000;46:207–214
  22. D'Amico AV, Tempany CM, Schultz D, et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology. 2003;62:1063–1067
  23. Shah JN, Wuu CS, Katz AE, et al. Improved biochemical control and clinical disease-free survival with intraoperative vs. preoperative preplanning for transperineal interstitial permanent prostate brachytherapy. Cancer J. 2006;12:289–297
  24. Matzkin H, Kaver I, Stenger A, et al. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: A prospective comparison of two seed implant methods-preplanning and intraoperative planning. Urology. 2003;62:497–502
  25. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  26. Papagikos MA, Deguzman AF, Rossi PJ, et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V(100) superior to D(90)?. Brachytherapy. 2005;4:252–258
  27. Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69:1472–1477
  28. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys. 2003;57:645–653
  29. Cesaretti JA, Stone NN, Skouteris VM, et al. Brachytherapy for the treatment of prostate cancer. Cancer J. 2007;13:302–312
  30. Beaulieu L, Aubin S, Taschereau R, et al. Dosimetric impact of the variation of the prostate volume and shape between pretreatment planning and treatment procedure. Int J Radiat Oncol Biol Phys. 2002;53:215–221
  31. Meijer GJ, van den Berg HA, Hurkmans CW, et al. Dosimetric comparison of interactive planned and dynamic dose calculated prostate seed brachytherapy. Radiother Oncol. 2006;80:378–384
  32. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376–1383
  33. Denham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the TROG 96.01 randomized controlled trial. Lancet Oncol. 2008;9:1058–1068

PII: S1078-1439(09)00401-3

doi: 10.1016/j.urolonc.2009.12.001

« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Article Tools

* Image Usage & Resolution